A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer.

Trial Profile

A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AXEPT
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2018.
    • 26 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2017.
    • 21 Jan 2017 Results (n=625, Data cut off August 31, 2016) assessing safety and tolerability, presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top